)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Xbrane Biopharma (XBRANE) investor relations material
Xbrane Biopharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary24 Oct, 2025
Executive summary
Ximluci launched in 24 countries, maintaining an 8% market share in Europe and leading among biosimilars in Italy and Germany; FDA approval in the US is delayed due to manufacturing site issues, with resubmission targeted for Q1 2026.
Xdivane clinical trial was initiated, targeting a $14 billion originator market, with full patient recruitment expected within 12 months and FDA submission planned for Q4 2027; launch is planned immediately post-patent expiry in December 2028.
Directed share issue raised SEK 240 million, significantly reducing debt, improving liquidity, and strengthening the cash position.
Divestment of XB003 and part of the organization to Alvotech completed, resulting in a SEK 168.9 million post-tax gain.
Financial highlights
Q3 2025 net revenue was SEK 10 million, including SEK 9–9.2 million profit share and a SEK -10 million adjustment for future profit sharing due to price pressure.
Administration expenses were SEK 8 million and R&D expenses SEK 10 million in Q3 2025, with SEK 2.8 million amortization of intangible assets.
Operating cash flow was SEK -49 million in Q3 2025; cash and cash equivalents at quarter-end were SEK 93.6–94 million.
Gross margin turned negative in Q3 2025 due to market price pressure; Jan–Sep 2025 gross margin was 61% (down from 90% year-over-year).
Profit for Jan–Sep 2025 was SEK 153.7 million, mainly due to the Alvotech divestment.
Outlook and guidance
Shipments to STADA are expected to continue in Q4 2025 and throughout 2026, converting inventory into cash.
Growth in Ximluci volumes is anticipated to resume in 2026, with a long-term goal of 20% market share in Europe.
Xdivane is expected to generate SEK 1 billion annually post-launch, with SEK 200 million in remaining development expenditure.
Current cash and a SEK 60 million loan facility are expected to sustain operations through 2026, but material uncertainty remains regarding long-term going concern.
Initiatives are underway to reduce Ximluci production costs for long-term competitiveness.
Ximluci FDA CRL resolution timeline?
Ximluci EU price pressure mitigation strategy?
Going concern risk mitigation plans?
Ximluci US resubmission timeline confirmation?
Update on Ximluci prefilled syringe launch.
Xdivane financing and manufacturing site selection.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Xbrane Biopharma earnings date
Q4 202531 Mar, 2026
Next Xbrane Biopharma earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Xbrane Biopharma is a biotechnology company that develops, manufactures and sells biosimilars worldwide. Many of the company's products are approved to treat cancer patients. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage